$1.13 Billion is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 110 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 220.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LLY | Buy | LILLY ELI & CO | $69,224,000 | +199.8% | 410,000 | +162.8% | 6.14% | +170.7% |
| SRPT | Buy | SAREPTA THERAPEUTICS INCcall | $63,081,000 | +199.5% | 370,000 | +146.7% | 5.60% | +170.4% |
| XBI | New | SPDR SER TRput | $42,234,000 | – | 300,000 | +100.0% | 3.75% | – |
| NVS | Buy | NOVARTIS AGsponsored adr | $40,510,000 | +63.5% | 429,000 | +50.5% | 3.60% | +47.6% |
| BMY | New | BRISTOL-MYERS SQUIBB CO | $38,769,000 | – | 625,000 | +100.0% | 3.44% | – |
| ONCR | New | ONCORUS INC | $28,395,000 | – | 903,111 | +100.0% | 2.52% | – |
| SGTX | New | SIGILON THERAPEUTICS INC | $26,061,000 | – | 567,460 | +100.0% | 2.31% | – |
| ABBV | Buy | ABBVIE INCcall | $24,109,000 | +120.2% | 225,000 | +80.0% | 2.14% | +98.9% |
| GNRC | Buy | GENERAC HLDGS INC | $24,029,000 | +85.2% | 105,663 | +57.7% | 2.13% | +67.3% |
| NICE | Buy | NICE LTDsponsored adr | $21,118,000 | +48.9% | 74,481 | +19.2% | 1.87% | +34.4% |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $16,589,000 | +120.4% | 745,900 | +46.3% | 1.47% | +98.9% |
| KURA | Buy | KURA ONCOLOGY INC | $15,399,000 | +39.8% | 471,494 | +31.2% | 1.37% | +26.3% |
| CCCC | New | C4 THERAPEUTICS INC | $14,601,000 | – | 443,824 | +100.0% | 1.30% | – |
| PANW | New | PALO ALTO NETWORKS INC | $13,459,000 | – | 37,871 | +100.0% | 1.19% | – |
| CERE | New | CEREVEL THERAPEUTICS HLDNG I | $13,457,000 | – | 811,665 | +100.0% | 1.19% | – |
| AUDC | New | AUDIOCODES LTDord | $11,818,000 | – | 428,971 | +100.0% | 1.05% | – |
| ZYME | Buy | ZYMEWORKS INC | $11,579,000 | +210.8% | 245,000 | +206.2% | 1.03% | +180.9% |
| NVS | New | NOVARTIS AGcall | $11,332,000 | – | 120,000 | +100.0% | 1.01% | – |
| BBIO | New | BRIDGEBIO PHARMA INC | $11,228,000 | – | 157,900 | +100.0% | 1.00% | – |
| FB | Buy | FACEBOOK INCcl a | $10,926,000 | +19.2% | 39,998 | +14.3% | 0.97% | +7.7% |
| MRK | New | MERCK & CO. INCcall | $10,634,000 | – | 130,000 | +100.0% | 0.94% | – |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $10,463,000 | +90.7% | 597,198 | +61.4% | 0.93% | +72.4% |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $9,374,000 | – | 60,000 | +100.0% | 0.83% | – |
| AVRO | Buy | AVROBIO INC | $9,143,000 | +115.7% | 655,874 | +101.5% | 0.81% | +95.0% |
| IMTX | Buy | IMMATICS N.V | $8,884,000 | +4.7% | 823,391 | +2.9% | 0.79% | -5.5% |
| CAMT | New | CAMTEK LTDord | $8,764,000 | – | 400,000 | +100.0% | 0.78% | – |
| VRNT | New | VERINT SYS INC | $8,532,000 | – | 127,000 | +100.0% | 0.76% | – |
| COGT | New | COGENT BIOSCIENCES INC | $8,259,000 | – | 735,434 | +100.0% | 0.73% | – |
| SBTX | New | SILVERBACK THERAPEUTICS INC | $8,075,000 | – | 174,261 | +100.0% | 0.72% | – |
| QURE | Buy | UNIQURE NV | $7,804,000 | +68.2% | 216,000 | +71.4% | 0.69% | +52.0% |
| BYSI | New | BEYONDSPRING INC | $7,296,000 | – | 598,000 | +100.0% | 0.65% | – |
| VRNA | Buy | VERONA PHARMA PLCsponsored ads | $7,235,000 | +15.9% | 1,033,603 | +3.4% | 0.64% | +4.7% |
| BLSA | New | BCLS ACQUISITION CORP | $6,891,000 | – | 625,000 | +100.0% | 0.61% | – |
| ORIC | New | ORIC PHARMACEUTICALS INC | $6,167,000 | – | 182,200 | +100.0% | 0.55% | – |
| NVMI | New | NOVA MEASURING INSTRUMENTS L | $5,515,000 | – | 78,113 | +100.0% | 0.49% | – |
| PRAX | New | PRAXIS PRECISION MEDICINES I | $5,502,000 | – | 100,000 | +100.0% | 0.49% | – |
| ARKO | New | ARKO CORP | $5,400,000 | – | 600,000 | +100.0% | 0.48% | – |
| VTGN | New | VISTAGEN THERAPEUTICS INC | $5,287,000 | – | 2,725,000 | +100.0% | 0.47% | – |
| IONS | New | IONIS PHARMACEUTICALS INC | $5,190,000 | – | 91,800 | +100.0% | 0.46% | – |
| CNCE | Buy | CONCERT PHARMACEUTICALS INC | $4,854,000 | +59.5% | 384,039 | +23.9% | 0.43% | +44.1% |
| DRNA | Buy | DICERNA PHARMACEUTICALS INC | $4,780,000 | +32.9% | 216,980 | +8.5% | 0.42% | +19.8% |
| GLTO | New | GALECTO INC | $4,669,000 | – | 391,787 | +100.0% | 0.41% | – |
| EPIX | Buy | ESSA PHARMA INC | $4,655,000 | +169.9% | 390,200 | +56.1% | 0.41% | +142.9% |
| STRO | New | SUTRO BIOPHARMA INC | $4,377,000 | – | 201,600 | +100.0% | 0.39% | – |
| KDNY | New | CHINOOK THERAPEUTICS INC | $3,198,000 | – | 201,666 | +100.0% | 0.28% | – |
| STTK | New | SHATTUCK LABS INC | $2,898,000 | – | 55,300 | +100.0% | 0.26% | – |
| SWTX | New | SPRINGWORKS THERAPEUTICS INC | $2,270,000 | – | 31,300 | +100.0% | 0.20% | – |
| YMTX | New | YUMANITY THERAPEUTICS INC | $2,217,000 | – | 130,434 | +100.0% | 0.20% | – |
| DYN | Buy | DYNE THERAPEUTICS INC | $2,100,000 | +48.6% | 100,000 | +42.9% | 0.19% | +33.8% |
| ALGS | New | ALIGOS THERAPEUTICS INC | $2,046,000 | – | 74,000 | +100.0% | 0.18% | – |
| IACA | New | ION ACQUISITION CORP 1 LTD | $1,766,000 | – | 150,000 | +100.0% | 0.16% | – |
| BCAB | New | BIOATLA INC | $1,701,000 | – | 50,000 | +100.0% | 0.15% | – |
| ETNB | Buy | 89BIO INC | $1,704,000 | +12.7% | 69,939 | +18.7% | 0.15% | +1.3% |
| INBX | New | INHIBRX INC | $1,424,000 | – | 43,182 | +100.0% | 0.13% | – |
| PIRS | New | PIERIS PHARMACEUTICALS INC | $1,375,000 | – | 550,000 | +100.0% | 0.12% | – |
| LSAQ | New | LIFESCI ACQUISITION II CORP | $1,062,000 | – | 100,000 | +100.0% | 0.09% | – |
| KRON | New | KRONOS BIO INC | $1,045,000 | – | 35,000 | +100.0% | 0.09% | – |
| ACRS | New | ACLARIS THERAPEUTICS INC | $971,000 | – | 150,000 | +100.0% | 0.09% | – |
| VINC | New | VINCERA PHARMA INC | $972,000 | – | 46,465 | +100.0% | 0.09% | – |
| CEREW | New | CEREVEL THERAPEUTICS HLDNG I*w exp 06/09/202 | $940,000 | – | 166,332 | +100.0% | 0.08% | – |
| SAGE | New | SAGE THERAPEUTICS INC | $740,000 | – | 8,554 | +100.0% | 0.07% | – |
| OLMA | New | OLEMA PHARMACEUTICALS INC | $731,000 | – | 15,200 | +100.0% | 0.06% | – |
| MGEN | New | MIRAGEN THERAPEUTICS INC | $502,000 | – | 30,497 | +100.0% | 0.04% | – |
| GMDA | New | GAMIDA CELL LTD | $336,000 | – | 40,000 | +100.0% | 0.03% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.